Lifecore Biomedical, Inc. (LFCR) stock
LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25
$6.42+0.02 (+0.31%)
Close on Nov 13, 2026Market cap $243.02MP/E –Yield –
Lifecore Biomedical total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Lifecore Biomedical's total debt was $978.00K at Sep 30, 2026. For fiscal 2025 it was $3.44M, down 96.6% from the year before. Over ten years it grew -22.2% a year on average. The highest annual figure on record is $164.90M in fiscal 2021.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | May 25, 2025 | $3.44M | -96.6% |
| FY2024 | May 26, 2024 | $101.76M | +20.0% |
| FY2023 | May 28, 2023 | $84.84M | -13.6% |
| FY2022 | May 29, 2022 | $98.18M | -40.5% |
| FY2021 | May 30, 2021 | $164.90M | +46.0% |
| FY2020 | May 31, 2020 | $112.92M | +16.4% |
| FY2019 | May 26, 2019 | $96.98M | +129.3% |
| FY2018 | May 27, 2018 | $42.30M | -10.5% |
| FY2017 | May 28, 2017 | $47.24M | -12.3% |
| FY2016 | May 29, 2016 | $53.85M | +26.6% |
| FY2015 | May 31, 2015 | $42.52M | +23.7% |
| FY2014 | May 25, 2014 | $34.37M | -14.7% |
| FY2013 | May 26, 2013 | $40.31M | -14.8% |
| FY2012 | May 27, 2012 | $47.32M | +138.6% |
| FY2011 | May 29, 2011 | $19.83M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2027CQ1 2026 | Sep 30, 2026 | $978.00K | +5.2% |
| Q2 FY2027CQ4 2025 | Jun 30, 2026 | $970.00K | -99.1% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $947.00K | -99.1% |
| Q4 FY2025CQ2 2025 | May 25, 2025 | $3.44M | -96.6% |
| Q3 FY2025CQ1 2025 | Feb 23, 2025 | $930.00K | -99.0% |
| Q2 FY2025CQ4 2024 | Nov 24, 2024 | $111.30M | +19.9% |
| Q1 FY2025CQ3 2024 | Aug 25, 2024 | $106.32M | +19.7% |
| Q4 FY2024CQ2 2024 | May 26, 2024 | $101.76M | +20.0% |
| Q3 FY2024CQ1 2024 | Feb 25, 2024 | $97.11M | -1.8% |
| Q2 FY2024CQ4 2023 | Nov 26, 2023 | $92.86M | -6.2% |
| Q1 FY2024CQ3 2023 | Aug 27, 2023 | $88.83M | -9.9% |
| Q4 FY2023CQ2 2023 | May 28, 2023 | $84.84M | -13.6% |
| Q3 FY2023CQ1 2023 | Feb 26, 2023 | $98.90M | +24.2% |
| Q2 FY2023CQ4 2022 | Nov 27, 2022 | $98.95M | -20.3% |
| Q1 FY2023CQ3 2022 | Aug 28, 2022 | $98.57M | -20.4% |
| Q4 FY2022CQ2 2022 | May 29, 2022 | $98.18M | -40.5% |
| Q3 FY2022CQ1 2022 | Feb 27, 2022 | $79.60M | -45.1% |
| Q2 FY2022CQ4 2021 | Nov 28, 2021 | $124.19M | +33.3% |
| Q1 FY2022CQ3 2021 | Aug 29, 2021 | $123.83M | +18.0% |
| Q4 FY2021CQ2 2021 | May 30, 2021 | $164.90M | +46.0% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $145.05M | +24.8% |
| Q2 FY2021CQ4 2020 | Nov 29, 2020 | $93.19M | -21.8% |
| Q1 FY2021CQ3 2020 | Aug 30, 2020 | $104.95M | +11.0% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $112.92M | +16.4% |
| Q3 FY2020CQ1 2020 | Feb 23, 2020 | $116.26M | +16.9% |
| Q2 FY2020CQ4 2019 | Nov 24, 2019 | $119.19M | +199.3% |
| Q1 FY2020CQ3 2019 | Aug 25, 2019 | $94.54M | +130.2% |
| Q4 FY2019CQ2 2019 | May 26, 2019 | $96.98M | +129.3% |
| Q3 FY2019CQ1 2019 | Feb 24, 2019 | $99.43M | +128.4% |
| Q2 FY2019CQ4 2018 | Nov 25, 2018 | $39.83M | -11.0% |
| Q1 FY2019CQ3 2018 | Aug 26, 2018 | $41.07M | -10.7% |
| Q4 FY2018CQ2 2018 | May 27, 2018 | $42.30M | -10.5% |
| Q3 FY2018CQ1 2018 | Feb 25, 2018 | $43.54M | -10.2% |
| Q2 FY2018CQ4 2017 | Nov 26, 2017 | $44.77M | -9.9% |
| Q1 FY2018CQ3 2017 | Aug 27, 2017 | $46.00M | -11.5% |
| Q4 FY2017CQ2 2017 | May 28, 2017 | $47.24M | -12.3% |
| Q3 FY2017CQ1 2017 | Feb 26, 2017 | $48.47M | – |
| Q2 FY2017CQ4 2016 | Nov 27, 2016 | $49.71M | – |
| Q1 FY2017CQ3 2016 | Aug 28, 2016 | $52.00M | – |
| Q4 FY2016CQ2 2016 | May 29, 2016 | $53.85M | – |
See a number that looks wrong?